| Connected Entity | Relationship Type |
Strength
(mentions)
|
Documents | Actions |
|---|---|---|---|---|
|
person
Sprout Capital VII, L.P.
|
Financial |
5
|
1 |
This document is page 11 of a confidential presentation (likely an investment prospectus for 'NLV-III') detailing the history and senior team of New Leaf Ventures. It features a timeline of funds raised from 1993 to 2007 under Sprout and New Leaf brands, totaling billions in capital. The page highlights the biography of Managing Director Philippe Chambon, detailing his history with Sprout, Boston Consulting Group, and Sandoz Pharmaceutical, as well as his numerous board memberships in the healthcare and biotech sectors. The document bears a House Oversight Committee control number.
This document is a confidential financial schedule detailing the 'Healthcare Technology Portfolio' performance for two funds: Sprout Capital VII, L.P. and Sprout Growth II, L.P., as of March 31, 2014. It lists specific portfolio companies (such as WebMD, Cephalon, and Adeza Biomedical), the vintage year of investment (ranging 1994-2003), investment costs, realized values, and Internal Rates of Return (IRR). The document bears a House Oversight Bates stamp (HOUSE_OVERSIGHT_024104), indicating it was part of a congressional investigation, likely related to financial probes involving entities connected to the broader Epstein investigation.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity